Profile
Jean-Francois Gimonet served as Deputy Chairman at ASTA Medica Oncology and Global Medico-Marketing Director at Baxter SAS.
He also served as Vice President-European Operations at Abraxis BioScience, Inc. from 2008 to 2011.
Gimonet holds a doctorate degree from Universite Paris Est.
Creteil Val De Marne.
Former positions of Jean-Francois Gimonet
| Companies | Position | End |
|---|---|---|
Abraxis BioScience, Inc.
 Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | Chief Operating Officer | 13/07/2009 |
| ASTA Medica Oncology | Director/Board Member | - |
Baxter SAS
 Baxter SAS Medical DistributorsDistribution Services Baxter SAS distributes pharmaceutical products for intravenous therapy, renal failure and other chronic and serious diseases. The company was founded by Ralph Falk and Don Baxter in 1931 and is headquartered in Guyancourt, France. | Sales & Marketing | - |
Training of Jean-Francois Gimonet
| Universite Paris Est Creteil Val De Marne | Doctorate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | Health Technology |
Baxter SAS
Baxter SAS Medical DistributorsDistribution Services Baxter SAS distributes pharmaceutical products for intravenous therapy, renal failure and other chronic and serious diseases. The company was founded by Ralph Falk and Don Baxter in 1931 and is headquartered in Guyancourt, France. | Distribution Services |
| ASTA Medica Oncology |
- Stock Market
- Insiders
- Jean-Francois Gimonet
